Evidence map›Paper›PMID 29595297›Full record

ArticlePsychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors2018

Alcohol, cannabis, and other drug use: Engagement and outcome in PTSD treatment.

Michele Bedard-Gilligan, Natalia Garcia, Lori A Zoellner, Norah C Feeny

Open access · hybridAbstract read
In one paragraph

Article in Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 4 pooled it
4.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Impact of self-reported cannabis use on veterans' intensive PTSD treatment outcomes.Psychological trauma : theory, research, practice and policy · 2026
    Article
  9. Understanding the Role of Endocannabinoids in Posttraumatic Stress Disorder.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Cannabinoid use is enhanced by stress and changes conditioned stress responses.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Michele Bedard-GilliganDepartment of Psychiatry and Behavioral Sciences, University of Washington.
Natalia GarciaDepartment of Psychology, University of Washington.
Lori A ZoellnerDepartment of Psychology, University of Washington.
Norah C FeenyDepartment of Psychology, Case Western Reserve University.
University of Washington · USCase Western Reserve University · US

Funding

Effectiveness of PTSD Treatment: Prolonged Exposure Therapy vs. ZoloftR01MH066347 · NIMH · UNIVERSITY OF WASHINGTON · PI ZOELLNER, LORI A · 2004 to 2014
$4.3M
Effectiveness of PTSD Treatment: PE vs ZoloftR01MH066348 · NIMH · CASE WESTERN RESERVE UNIVERSITY · PI FEENY, NORAH C · 2004 to 2014
$4.3M
Marijuana Use, Extinction Learning, and Exposure Therapy in Individuals with PTSDR34DA040034 · NIDA · UNIVERSITY OF WASHINGTON · PI BEDARD-GILLIGAN, MICHELE A · 2016 to 2018
$537k
Developing a Brief Early Cognitive Intervention for PTSD and Alcohol MisuseR34AA022966 · NIAAA · UNIVERSITY OF WASHINGTON · PI BEDARD-GILLIGAN, MICHELE A · 2015 to 2017
$536k
NIAAA NIH HHS R34 AA022966NIDA NIH HHS R34 DA040034NIMH NIH HHS R01 MH066347NIMH NIH HHS R01 MH066348
6 · The paper itself

Abstract

The co-occurrence of posttraumatic stress disorder (PTSD) and substance use is related to poorer outcome and increased dropout from trauma-focused treatment. Investigating PTSD and substance use can inform the intervention approaches. Exploring cannabis use in particular is especially important because rates of cannabis use have been increasing with recent legalization trends. A better understanding of how substance use is associated with treatment processes and outcome for individuals with PTSD is needed to enhance care. In this study, both lifetime diagnoses of alcohol and drug use disorders and current alcohol and drug use severity were examined in 200 men and women with chronic PTSD who received either prolonged exposure (PE) or sertraline. No lifetime or current alcohol use variables predicted dropout, adherence, or poorer outcome. However, lifetime diagnosis of both an alcohol and drug disorder (OR = 3.42) and recent cannabis use (OR = 3.38) strongly predicted higher dropout. Recent cannabis use and drug use severity predicted poorer adherence to PE (β = -.22 to -.29) but not to sertraline. Drug use severity (β = -.22) also predicted worse treatment outcome, as did lifetime diagnosis of an alcohol and drug disorder (β = -.48). Overall, patients with drug use improved with treatment but had less treatment retention, adherence, and symptom reduction. Strategies to increase engagement and retention may be indicated for these patients. Individuals who are using cannabis or other drugs may be at higher risk for not completing PTSD treatment, potentially prolonging the cycle of PTSD and substance use. (PsycINFO Database Record

Indexed as

AdultAlcohol DrinkingCombined Modality TherapyFemaleHumansImplosive TherapyMaleMarijuana SmokingSelective Serotonin Reuptake InhibitorsSertralineStress Disorders, Post-TraumaticSubstance-Related DisordersTreatment OutcomeSelective Serotonin Reuptake InhibitorsSertraline

Identifiers

PMID29595297
PMCPMC9377391
OpenAlexW2794448262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.